Trials / Completed
CompletedNCT02665650
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Affimed GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AFM13 | |
| BIOLOGICAL | Pembrolizumab |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2019-01-01
- Completion
- 2019-03-01
- First posted
- 2016-01-28
- Last updated
- 2019-05-16
Locations
18 sites across 2 countries: United States, Spain
Source: ClinicalTrials.gov record NCT02665650. Inclusion in this directory is not an endorsement.